Quantcast

The management of patients with limited-stage classical Hodgkin lymphoma.

Research paper by Mary K MK Gospodarowicz, Ralph M RM Meyer

Indexed on: 25 Nov '06Published on: 25 Nov '06Published in: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program



Abstract

The term limited-stage Hodgkin lymphoma refers to those patients with stage I-II disease and an absence of bulky disease. Among those patients with classical Hodgkin lymphoma, approximately one-third of patients will fall into this category. As long-term disease control can now be anticipated in more than 90% of these patients, management strategies must increasingly address the need to reduce the long-term treatment-related risks. Current treatment options include use of combined modality therapy that includes an abbreviated course of chemotherapy and involved-field radiation or treatment with chemotherapy, currently consisting of ABVD, as a single modality. The choice of treatment between these two options involves specific trade-offs that must balance issues of disease control against long-term risk of late effects.